The role of biologics into the management of psoriasis: A consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung;Stellenwert von biologics in der psoriasis-therapie: Ein konsensus-papier der Arbeitsgruppe Psoriasis, Arbeitsgemeinschaft Dermatologische Forschung

JDDG - Journal of the German Society of Dermatology

Volumn 1, Issue 8, 2003, Pages 620-628

  Boehncke, Wolf Henning ^a   Friedrich, Markus ^b   Mrowietz, Ulrich ^f   Reich, Kristian ^c   Rosenbach, Thomas ^d   Sticherling, Michael ^e   Thaçi, Diamant ^a  

^a GOETHE UNIVERSITY   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d Hautarztpraxis   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f NONE

Author keywords

Alefacept; Biologics; Etanercept; Infliximab; Psoriasis therapy

Indexed keywords

ALEFACEPT; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT;

ANAPHYLAXIS; CELL INTERACTION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ECONOMIC ASPECT; HUMAN; IMMUNOPATHOGENESIS; INFECTION; LEGAL ASPECT; PHOTOTHERAPY; PSORIASIS; REVIEW; SIDE EFFECT; ARTHRITIS, PSORIATIC; CONSENSUS DEVELOPMENT; DRUG APPROVAL; DRUG COST; ECONOMICS; FOOD AND DRUG ADMINISTRATION; GERMANY; IMMUNOLOGY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; DRUG APPROVAL; DRUG COSTS; GERMANY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0141425546     PISSN: 16100379     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1610-0387.2003.03014.x     Document Type: Review

References (28)

1. Bos JD and De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20: 40-46.
2. Reich K. Regulatory functions of IL-10 in the cutaneous immune system, a lesson to learn from experimental IL-10 therapy of inflammatory skin disease. G Ital Dermatol Venereol 2001; 136: 351-370.
3. Friederich M, Sterry W, Asadullah, K. Neue Entwicklungen in der systemischen Psoriasistherapie. JDDG 2003; 1: 12-21.
4. Boehncke W-H, Schön MP. Interfering with leukocyte rolling - a promising therapeutic approach in inflammatory skin disorders? Trends Pharmacol Sci 2003; 24: 49-52.
5. van de Kerkhof PC, de Hoop D, de Korte J, Cobelens SA, Kuipers M. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000; 200: 292-298.
6. Weinberg JM, Saini R. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept. Cutis 2003; 71: 25-29.
7. Weinberg JM, Tutrone WD. Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept. Cutis 2003; 71: 41-45.
8. Mrowietz U. Advances in systemic therapy for psoriasis. Clin Exp Dermatol 2001; 26: 362-367.
9. Mrowietz U. Treatment targeted to cell surface epitopes. Clin Exp Dermatol 2002; 27: 591-596.
10. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebocontrolled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-833.
11. Mease PJ, Goffe BS, Metz J, Vander Stoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-390.
12. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2000; 138: 591-600.
13. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001: 345: 248-255.
14. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847.
15. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol. 2002; 41: 449-452.
16. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recal citrant psoriasis: a report of 2 cases. Arch Dermatol. 2002; 138: 644-648.
17. Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO. Generalised pustular psoriasis induced by cyclosporin after withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology 2002; 205:213-216.
18. Krueger GG. Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis. Expert Opin Biol Ther 2002; 2: 431-441.
19. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, Kalden-Nemeth D, Kalden JR, Manger B. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002; 47:506-512.
20. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin Exp Rheumatol 2000; 18: 732-774.
21. Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 2002; 22: 227-232.
22. Mease P. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. Clin Exp Rheumatol 2002; 20: S116-S121.
23. Kraan MC, van Kuijk AW, Dinant HJ, Goedkoop AY, Smeets TJ, de Rie MA, Dijkmans BA, Vaishnaw AK, Bos JD, Tak PP. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002; 46: 2776-2784.
24. Dt Ärztebl 2002; 99: A1069.
25. Traupe H, Robra BP. Schuppenflechte. Robert Koch Institut: Gesundheitsberichterstattung des Bundes, Heft 11, 2002.
26. Sander P, Stücker M, Hoffmann M, Hoffmann K, Altmeyer P. Topische Dreifachtherapie der chronischen stationären Psoriasis (CSP). Aktuelle Dermatologie 2001; 27: 173-177.
27. MERG GmbH, Forschungsgruppe Medizinische Ökonomie. Lebensqualitäts- und Krankheitskostenstudie: Patienten mit chronischer Plaque-Psoriasis in Deutschland. München, 2003.
28. MERG GmbH, Forschungsgruppe Medizinische Ökonomie. Beschreibung der stationären Versorgung von Patienten mit Psoriasis vulgaris. München, 2003.